This past Thursday, the FDA’s advisory committee on vaccines and similar biological products met to discuss COVID-19 boosters for this fall. They voted in favor of updating the vaccines based on Omicron XBB, a variant lineage that has dominated both in the U.S. and globally this year.
Read MoreSources and updates for the week of May 28 include new Long COVID papers, FDA approval for Paxlovid, bivalent vaccine protection, and more.
Read MoreSources and updates for the week of April 16 include new Long COVID research, bivalent booster effectiveness, air quality in schools, and more.
Read MoreSources and updates for the week of April 9 include Omicron boosters, federal Long COVID progress, ventilation improvements in K-12 schools, and more.
Read MoreSources and updates for the week of January 29 include wastewater surveillance in New York State, bivalent boosters vs. XBB.1.5, the potential end of the global health emergency, and more.
Read More
On Thursday, the FDA’s Vaccines and Related Biological Products Advisory Committee (or VRBPAC) met to discuss the future of COVID-19 vaccines. While the committee readily agreed that our current, Omicron-specific shots are working well and should be used more broadly, it had a hard time answering other questions about future vaccine regimens—largely due to a lack of good data.
Read MoreSources and updates for the week of January 22 include respiratory virus hospitalizations, new excess death estimates, wastewater testing on airplanes, and more.
Read MoreSources and updates for the week of December 11 include America’s Health Rankings, bivalent boosters for kids, and more.
Read MoreSources and updates for the week of November 27 include more data on bivalent booster shots, Long COVID research, and more.
Read MoreSources and updates for the week of November 20 include mortality trends, bivalent boosters, perceptions of COVID-19 trends, and more.
Read More